Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry A Molitor

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
American Journal of Respiratory and Critical Care Medicine|March 2, 2021
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled TrialRoham T Zamanian, David Badesch, Lorinda Chung, et al.
Arthritis and Rheumatism|June 3, 2008
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArnold E Postlethwaite, Weng Kee Wong, Philip Clements, et al.
Seminars in Arthritis and Rheumatism|April 9, 2014
Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort studyVivien M Hsu, Lorinda Chung, Laura K Hummers, et al.
Blood|April 25, 2007
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyRichard A Nash, Peter A McSweeney, Leslie J Crofford, et al.
Arthritis and Rheumatism|October 31, 2009
Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trialEva C Koffeman, Mark Genovese, Diane Amox, et al.
The Journal of Rheumatology|May 17, 2011
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysisRoozbeh Sharif, Marvin J Fritzler, Maureen D Mayes, et al.
Arthritis Care & Research|August 29, 2013
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registryLorinda Chung, Robyn T Domsic, Bharathi Lingala, et al.
The Journal of Rheumatology|October 3, 2018
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS RegistryVivien M Hsu, Lorinda Chung, Laura K Hummers, et al.
Clinical and Experimental Rheumatology|December 3, 2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registryLorinda Chung, Robert M Fairchild, Daniel E Furst, et al.
Rheumatology (Oxford, England)|April 20, 2023
CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilizationSarah Luebker, Tracy M Frech, Shervin Assassi, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
American Journal of Respiratory and Critical Care Medicine|March 2, 2021
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled TrialRoham T Zamanian, David Badesch, Lorinda Chung, et al.
Arthritis and Rheumatism|June 3, 2008
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArnold E Postlethwaite, Weng Kee Wong, Philip Clements, et al.
Seminars in Arthritis and Rheumatism|April 9, 2014
Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort studyVivien M Hsu, Lorinda Chung, Laura K Hummers, et al.
Blood|April 25, 2007
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyRichard A Nash, Peter A McSweeney, Leslie J Crofford, et al.
Arthritis and Rheumatism|October 31, 2009
Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trialEva C Koffeman, Mark Genovese, Diane Amox, et al.
The Journal of Rheumatology|May 17, 2011
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysisRoozbeh Sharif, Marvin J Fritzler, Maureen D Mayes, et al.
Arthritis Care & Research|August 29, 2013
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registryLorinda Chung, Robyn T Domsic, Bharathi Lingala, et al.
The Journal of Rheumatology|October 3, 2018
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS RegistryVivien M Hsu, Lorinda Chung, Laura K Hummers, et al.
Clinical and Experimental Rheumatology|December 3, 2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registryLorinda Chung, Robert M Fairchild, Daniel E Furst, et al.
Rheumatology (Oxford, England)|April 20, 2023
CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilizationSarah Luebker, Tracy M Frech, Shervin Assassi, et al.
Pageof 5